Sobi makes billion-dollar bid for CTI Biopharma

Sobi has made a bid for US CTI Biopharma worth SEK 17 billion. The transaction will be financed through a rights issue and the largest shareholder Investor will subscribe for its pro rata share. With the acquisition, Sobi aims to broaden the product portfolio with myelofibrosis treatment Vonjo and strengthen its presence in the US.

Read the article at biostock.se:

https://www.biostock.se/en/2023/05/sobi-makes-billion-dollar-bid-for-cti-biopharma/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/